Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kiniksa Pharmaceuticals International, plc KNSA

Healthcare  —  Drug Manufacturers Specialty & Generic
75.08 (0.26) (0.35%) as of 25 Sep
Market cap
$5.9B
P/E
70.2×
Cash Flow Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more quarters

 180.86 202.13 214.27 243.60
Revenue Growth 61.17% 64.95% 55.51% 55.36%
Cost of Revenue 20.26 20.95 20.80 23.57
Gross Profit 160.60 181.18 193.47 220.03
R&D Expenses 24.17 34.61 27.48 40.90
SG&A Expenses 49.10 56.78 61.15 63.87
Operating Income 24.02 19.77 29.27 27.19
Non-operating Income/Expense 3.14 3.50 3.41 3.95
EBT 27.16 23.27 32.68 31.15
Income Tax Provision 8.72 9.07 10.09 5.71
Income after Tax 18.44 14.20 22.59 25.43
Net Income Common 18.44 14.20 22.59 25.43
EPS (Basic) 0.25 0.19 0.30 0.33
EPS (Diluted) 0.23 0.17 0.27 0.30
Shares (Basic, Weighted) 74.72 74.20 76.52 77.58
Shares (Diluted, Weighted) 80.04 78.98 82.41 83.40
Gross Margin 88.80% 89.64% 90.29% 90.32%
EBIT Margin 13.28% 9.78% 13.66% 11.16%
EBT margin 15.02% 11.51% 15.25% 12.79%
Net Profit Margin 10.19% 7.02% 10.54% 10.44%
EBITDA 24.41 20.24 29.74 27.67
EBIT 24.02 19.77 29.27 27.19
Income from Continuous Operations 18.44 14.20 22.59 25.43
Consolidated Net Income/Loss 18.44 14.20 22.59 25.43
EPS (Basic, from Continuous Ops) 0.25 0.19 0.30 0.33
EPS (Diluted, from Cont. Ops) 0.23 0.18 0.27 0.30
EPS (Basic, Consolidated) 0.25 0.19 0.30 0.33
EPS (Diluted, Consolidated) 0.23 0.18 0.27 0.30
Shares (Diluted, Average) 80.04 81.57 82.41 83.40
EBITDA Margin 13.49% 10.01% 13.88% 11.36%
Operating Cash Flow Margin 18.62% 26.66% 23.43% 19.37%

Fold the line items

In millions of $ except per-share values · columns are period end dates